Memo Therapeutics closes Series B financing at CHF37 M following oversubscribed CHF23 M extension. Proceeds will be used to advance antibody against BK virus through Phase 2 clinical development.

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center